CClinicalTrials.gg
Not yet recruitingNCT07747675Updated Aug 5, 2026

Cognitive Intervention for Cognitive Impairment

An interventional study of cognitive intervention in Cognitive Intervention, Mild Cognitive Impairment and Elderly Adults, sponsored by Instituto Mexicano del Seguro Social. Not yet recruiting. Open to participants aged 65 Years to 95 Years. Per ClinicalTrials.gov, last updated 2026-08-05.

Sponsored by Instituto Mexicano del Seguro Social · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
102
Allocation
Randomized
Ages
65 Years to 95 Years
Sex
All
01

Study summary

Mild cognitive impairment is characterized by cognitive dysfunction without impairment in instrumental activities of daily living, with aging being the primary risk factor. Cognitive interventions employ stimulation and training techniques to address this impairment.

Objective: To determine the effect of a cognitive intervention on mild cognitive impairment in older adults with type 2 diabetes mellitus.

Methods: A double-blind, randomized clinical trial involving 102 patients, who will be assigned to either a control group or an intervention group. Data collection will utilize a sociodemographic profile questionnaire and the Montreal Cognitive Assessment (MoCA). The cognitive intervention will be implemented over an average period of two months per subgroup, consisting of eight weekly, 60-minute sessions. Analysis will be conducted using descriptive statistics, and a linear mixed-effects model for repeated measures will be applied to evaluate the intervention's effect.

Read the detailed description

Potential participants will be evaluated in Education Classroom 1 at UMF No. 7. After obtaining written informed consent, two instruments will be administered to the patients. First, a questionnaire gathering sociodemographic characteristics will be administered. The second measurement instrument will be the Montreal Cognitive Assessment (MoCA).

Randomization and assignment: Eligible participants will be assigned via simple random selection in a 1:1 ratio using a computer-generated block randomization sequence. Group assignment will be concealed using opaque, sealed, and sequentially numbered envelopes managed by an independent study coordinator who is not involved in patient care or assessment. Intervention phase (weeks 1 to 8): Group 1 (intervention) will receive the intervention based on the cognitive psychostimulation program outlined in the INAPAM Cognitive Stimulation Manual for Older Adults. Group 2 (control): Patients will receive an intervention delivered by social work staff, consisting of an Active and Healthy Aging program.

Upon completion of the intervention, the MoCA scale will be administered again to evaluate the effectiveness of the implemented program.

02

Conditions studied

  • Cognitive Intervention
  • Mild Cognitive Impairment
  • Elderly Adults
  • Diabetes Mellitus

Keywords

  • Mild Cognitive Impairment
  • Cognitive intervention
  • Elderly adults
  • Diabetes Mellitus
03

Who can participate

Ages eligible
65 Years to 95 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Affiliation with IMSS Aguascalientes Family Medicine Unit (UMF) No. 7; age 65 to 95 years; male or female; known diagnosis of type 2 diabetes mellitus; any level of education; any occupation; presence of mild cognitive impairment; availability to attend cognitive intervention sessions; and signing of informed consent.

Exclusion criteria

Exclusion Criteria:

  • Patients with disabling hearing and/or visual impairments, patients with paralysis, and patients with severe psychiatric illness.
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
102 participants (estimated)

Study arms

  • No intervention
    Control group

    The control group will receive an intervention delivered by social work staff, involving the implementation of an Active and Healthy Aging program that includes cognitive rehabilitation workshops as well as physical, emotional, social, and functional stimulation, with the aim of providing rehabilitation to older adults in the emotional, functional, and cognitive domains.

  • Experimental
    Intervention gruop

    The intervention will be administered by two family medicine physicians trained in implementing the cognitive intervention. This intervention will utilize a cognitive-psychostimulation program based on INAPAM's Cognitive Stimulation Manual for Older Adults, which provides participants with tools for continuous stimulation, addressing memory, attention, language, executive and visuospatial functions, abstraction, and orientation.

    Other: cognitive intervention

Interventions

  • Othercognitive intervention

    The intervention will be administered by two family medicine physicians trained in implementing the cognitive intervention. This intervention will utilize a cognitive-psychostimulation program based on INAPAM's Cognitive Stimulation Manual for Older Adults, which provides participants with tools for continuous stimulation, addressing memory, attention, language, executive and visuospatial functions, abstraction, and orientation.

05

What researchers measure

Primary outcomes

  1. Score on the MoCA scale

    Assessed using the MoCA scale (range of 0 to 30 points). Results are classified as follows: 0-25 points indicate mild cognitive impairment, while 26-30 points are considered normal.

    Time frame: Change from baseline (Week 0) to Week 8

06

Study locations

No study locations are listed for this record.

07

References and documents

Individual participant data

Plan to share: Yes — Anonymized individual data regarding demographic and anthropometric variables and primary clinical outcomes will be shared upon a justified written request.

Supporting information: Sap, Analytic code

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07747675
Lead sponsor
Instituto Mexicano del Seguro Social
Responsible party
Erika Lorena Vega Silva (Doctor, Instituto Mexicano del Seguro Social) — Principal investigator
First posted
Aug 5, 2026
Start date
Aug 3, 2026 (estimated)
Primary completion
Sep 30, 2026 (estimated)
Completion
Oct 15, 2026 (estimated)
Last update
Aug 5, 2026

Study contacts

Erika L Vega Silva, Dr.
Contact
draevega3606@gmail.com
449-918-0610 ext. 41465
Diana L García Zepeda, Dr.
Contact
diana.zep25@gmail.com
449-918-0610 ext. 41465
Erika L Vega Silva, Dr.
principal investigator · Instituto Mexicano del Seguro Social

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion